|
US6140466A
(en)
|
1994-01-18 |
2000-10-31 |
The Scripps Research Institute |
Zinc finger protein derivatives and methods therefor
|
|
US7262055B2
(en)
|
1998-08-25 |
2007-08-28 |
Gendaq Limited |
Regulated gene expression in plants
|
|
AU698152B2
(en)
|
1994-08-20 |
1998-10-22 |
Gendaq Limited |
Improvements in or relating to binding proteins for recognition of DNA
|
|
GB9824544D0
(en)
*
|
1998-11-09 |
1999-01-06 |
Medical Res Council |
Screening system
|
|
GB9710809D0
(en)
|
1997-05-23 |
1997-07-23 |
Medical Res Council |
Nucleic acid binding proteins
|
|
US6410248B1
(en)
|
1998-01-30 |
2002-06-25 |
Massachusetts Institute Of Technology |
General strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites
|
|
ATE466952T1
(en)
|
1998-03-02 |
2010-05-15 |
Massachusetts Inst Technology |
POLY ZINC FINGER PROTEINS WITH IMPROVED LINKERS
|
|
ATE336578T1
(en)
*
|
1998-03-17 |
2006-09-15 |
Gendaq Ltd |
NUCLEIC ACID BINDING PROTEINS
|
|
US6534261B1
(en)
|
1999-01-12 |
2003-03-18 |
Sangamo Biosciences, Inc. |
Regulation of endogenous gene expression in cells using zinc finger proteins
|
|
US7013219B2
(en)
|
1999-01-12 |
2006-03-14 |
Sangamo Biosciences, Inc. |
Regulation of endogenous gene expression in cells using zinc finger proteins
|
|
US6453242B1
(en)
|
1999-01-12 |
2002-09-17 |
Sangamo Biosciences, Inc. |
Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
|
|
US6599692B1
(en)
|
1999-09-14 |
2003-07-29 |
Sangamo Bioscience, Inc. |
Functional genomics using zinc finger proteins
|
|
US7070934B2
(en)
|
1999-01-12 |
2006-07-04 |
Sangamo Biosciences, Inc. |
Ligand-controlled regulation of endogenous gene expression
|
|
US6794136B1
(en)
|
2000-11-20 |
2004-09-21 |
Sangamo Biosciences, Inc. |
Iterative optimization in the design of binding proteins
|
|
US7030215B2
(en)
|
1999-03-24 |
2006-04-18 |
Sangamo Biosciences, Inc. |
Position dependent recognition of GNN nucleotide triplets by zinc fingers
|
|
US20030104526A1
(en)
|
1999-03-24 |
2003-06-05 |
Qiang Liu |
Position dependent recognition of GNN nucleotide triplets by zinc fingers
|
|
US7943731B1
(en)
|
1999-08-11 |
2011-05-17 |
Massachusetts Institute Of Technology |
Dimerizing peptides
|
|
DE60023936T2
(en)
|
1999-12-06 |
2006-05-24 |
Sangamo Biosciences Inc., Richmond |
METHODS OF USING RANDOMIZED ZINCFINGER PROTEIN LIBRARIES FOR IDENTIFYING GENERAL FUNCTIONS
|
|
AU2693501A
(en)
|
2000-01-24 |
2001-07-31 |
Gendaq Ltd |
Nucleic acid binding polypeptides characterized by flexible linkers connected nucleic acid binding modules
|
|
WO2001083819A2
(en)
|
2000-04-28 |
2001-11-08 |
Sangamo Biosciences, Inc. |
Methods for designing exogenous regulatory molecules
|
|
US7923542B2
(en)
|
2000-04-28 |
2011-04-12 |
Sangamo Biosciences, Inc. |
Libraries of regulatory sequences, methods of making and using same
|
|
ATE374249T1
(en)
|
2000-04-28 |
2007-10-15 |
Sangamo Biosciences Inc |
DATABASES OF REGULATORY SEQUENCES, METHODS OF THEIR PRODUCTION AND USE
|
|
AU2001257421A1
(en)
|
2000-04-28 |
2001-11-12 |
Sangamo Biosciences, Inc. |
Pharmacogenomics and identification of drug targets by reconstruction of signal transduction pathways based on sequences of accessible regions
|
|
AU2001252428A1
(en)
*
|
2000-05-08 |
2001-11-20 |
Gendaq Limited |
Nucleic acid binding polypeptides
|
|
AU2001278496A1
(en)
*
|
2000-07-21 |
2002-02-05 |
Syngenta Participations Ag |
Zinc finger domain recognition code and uses thereof
|
|
WO2002018648A2
(en)
*
|
2000-08-25 |
2002-03-07 |
President And Fellows Of Harvard College |
Analysis of binding interactions
|
|
US6905816B2
(en)
|
2000-11-27 |
2005-06-14 |
Intelligent Medical Devices, Inc. |
Clinically intelligent diagnostic devices and methods
|
|
EP1341914A2
(en)
|
2000-12-07 |
2003-09-10 |
Sangamo Biosciences Inc. |
Regulation of angiogenesis with zinc finger proteins
|
|
US7067317B2
(en)
|
2000-12-07 |
2006-06-27 |
Sangamo Biosciences, Inc. |
Regulation of angiogenesis with zinc finger proteins
|
|
CA2435394C
(en)
|
2001-01-22 |
2018-01-09 |
Sangamo Biosciences, Inc. |
Modified zinc finger binding proteins
|
|
WO2002057308A2
(en)
*
|
2001-01-22 |
2002-07-25 |
Sangamo Biosciences, Inc. |
Zinc finger polypeptides and their use
|
|
EP1435779A4
(en)
|
2001-09-24 |
2005-06-01 |
Sangamo Biosciences Inc |
Modulation of stem cells using zinc finger proteins
|
|
US7262054B2
(en)
|
2002-01-22 |
2007-08-28 |
Sangamo Biosciences, Inc. |
Zinc finger proteins for DNA binding and gene regulation in plants
|
|
BRPI0307383B1
(en)
|
2002-01-23 |
2019-12-31 |
The Univ Of Utah Research Foundation |
directed genetic recombination method in host plant cell
|
|
SI1504108T1
(en)
|
2002-02-01 |
2013-07-31 |
Oxford Biomedica (Uk) Limited |
Lentiviral vector
|
|
CA2493364A1
(en)
|
2002-07-26 |
2004-02-12 |
Basf Plant Science Gmbh |
Inversion of the negative-selective effect of negative marker proteins using selection methods
|
|
US7361635B2
(en)
|
2002-08-29 |
2008-04-22 |
Sangamo Biosciences, Inc. |
Simultaneous modulation of multiple genes
|
|
CA2497913C
(en)
|
2002-09-05 |
2014-06-03 |
California Institute Of Technology |
Use of chimeric nucleases to stimulate gene targeting
|
|
GB0228289D0
(en)
|
2002-12-04 |
2003-01-08 |
Genome Inst Of Singapore Nat U |
Method
|
|
US7888121B2
(en)
|
2003-08-08 |
2011-02-15 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
|
US8409861B2
(en)
|
2003-08-08 |
2013-04-02 |
Sangamo Biosciences, Inc. |
Targeted deletion of cellular DNA sequences
|
|
US20120196370A1
(en)
|
2010-12-03 |
2012-08-02 |
Fyodor Urnov |
Methods and compositions for targeted genomic deletion
|
|
US11311574B2
(en)
|
2003-08-08 |
2022-04-26 |
Sangamo Therapeutics, Inc. |
Methods and compositions for targeted cleavage and recombination
|
|
WO2005014791A2
(en)
|
2003-08-08 |
2005-02-17 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
|
CA2539439C
(en)
|
2003-09-19 |
2012-10-23 |
Sangamo Biosciences, Inc. |
Engineered zinc finger proteins for regulation of gene expression
|
|
US7972854B2
(en)
|
2004-02-05 |
2011-07-05 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
|
JP4564052B2
(en)
|
2004-04-08 |
2010-10-20 |
サンガモ バイオサイエンシズ インコーポレイテッド |
Methods and compositions for modulating myocardial contractility
|
|
US20050282193A1
(en)
|
2004-04-23 |
2005-12-22 |
Bulyk Martha L |
Space efficient polymer sets
|
|
CA2579677A1
(en)
|
2004-09-16 |
2006-03-30 |
Sangamo Biosciences, Inc. |
Compositions and methods for protein production
|
|
JP4988606B2
(en)
|
2005-02-28 |
2012-08-01 |
サンガモ バイオサイエンシズ インコーポレイテッド |
Anti-angiogenic methods and compositions
|
|
US20090263900A1
(en)
|
2008-04-14 |
2009-10-22 |
Sangamo Biosciences, Inc. |
Linear donor constructs for targeted integration
|
|
CA2615532C
(en)
|
2005-07-26 |
2016-06-28 |
Sangamo Biosciences, Inc. |
Targeted integration and expression of exogenous nucleic acid sequences
|
|
JP5266210B2
(en)
|
2006-05-25 |
2013-08-21 |
サンガモ バイオサイエンシズ インコーポレイテッド |
Modified cleavage half-domain
|
|
ES2378333T3
(en)
|
2006-05-25 |
2012-04-11 |
Sangamo Biosciences, Inc. |
Methods and compositions for gene inactivation
|
|
CN105296527B
(en)
|
2006-08-11 |
2020-11-27 |
陶氏益农公司 |
Zinc finger nuclease-mediated homologous recombination
|
|
CA2667414C
(en)
*
|
2006-11-13 |
2015-12-29 |
Sangamo Biosciences, Inc. |
Methods and compositions for modification of the human glucocorticoid receptor locus
|
|
ES2586210T3
(en)
|
2006-12-14 |
2016-10-13 |
Sangamo Biosciences, Inc. |
Optimized non-canon zinc finger proteins
|
|
US8110379B2
(en)
|
2007-04-26 |
2012-02-07 |
Sangamo Biosciences, Inc. |
Targeted integration into the PPP1R12C locus
|
|
CN101883850B
(en)
|
2007-07-12 |
2014-11-12 |
桑格摩生物科学股份有限公司 |
Methods and compositions for inactivating alpha-1,6 fucosyltransferase (FUT 8) gene expression
|
|
CA2700231C
(en)
|
2007-09-27 |
2018-09-18 |
Sangamo Biosciences, Inc. |
Rapid in vivo identification of biologically active nucleases
|
|
US11235026B2
(en)
|
2007-09-27 |
2022-02-01 |
Sangamo Therapeutics, Inc. |
Methods and compositions for modulating PD1
|
|
PT2205749T
(en)
|
2007-09-27 |
2016-07-20 |
Dow Agrosciences Llc |
Engineered zinc finger proteins targeting 5-enolpyruvyl shikimate-3-phosphate synthase genes
|
|
US8563314B2
(en)
|
2007-09-27 |
2013-10-22 |
Sangamo Biosciences, Inc. |
Methods and compositions for modulating PD1
|
|
EP2205752B1
(en)
|
2007-10-25 |
2016-08-10 |
Sangamo BioSciences, Inc. |
Methods and compositions for targeted integration
|
|
WO2009130695A2
(en)
|
2008-04-21 |
2009-10-29 |
Danziger Innovation Ltd. |
Plant viral expression vectors and use of same for generating genotypic variations in plant genomes
|
|
US10316288B2
(en)
|
2008-04-30 |
2019-06-11 |
Sanbio, Inc. |
Neural regenerating cells with alterations in DNA methylation
|
|
JP2011521643A
(en)
|
2008-05-28 |
2011-07-28 |
サンガモ バイオサイエンシーズ， インコーポレイテッド |
Composition for linking a DNA binding domain and a cleavage domain
|
|
WO2009151591A2
(en)
|
2008-06-10 |
2009-12-17 |
Sangamo Biosciences, Inc. |
Methods and compositions for generation of bax- and bak-deficient cell lines
|
|
KR20160015400A
(en)
|
2008-08-22 |
2016-02-12 |
상가모 바이오사이언스 인코포레이티드 |
Methods and compositions for targeted single-stranded cleavage and targeted integration
|
|
US8153399B2
(en)
|
2008-10-29 |
2012-04-10 |
Sangamo Biosciences, Inc. |
Methods and compositions for inactivating glutamine synthetase gene expression
|
|
JP5681114B2
(en)
|
2008-12-04 |
2015-03-04 |
サンガモ バイオサイエンシーズ， インコーポレイテッド |
Rat genome editing using zinc finger nuclease
|
|
BRPI0922641B1
(en)
|
2008-12-17 |
2021-10-26 |
Dow Agrosciences Llc |
METHOD OF INTEGRATION OF ONE OR MORE EXOGENOUS NUCLEIC ACID SEQUENCES INTO THE GENOME OF A PLANT CELL
|
|
US8551945B2
(en)
|
2009-02-04 |
2013-10-08 |
Sangamo Biosciences, Inc. |
Methods and compositions for treating neuropathies
|
|
WO2010107493A2
(en)
|
2009-03-20 |
2010-09-23 |
Sangamo Biosciences, Inc. |
Modification of cxcr4 using engineered zinc finger proteins
|
|
AU2010235161B2
(en)
|
2009-04-09 |
2015-01-22 |
Sangamo Therapeutics, Inc. |
Targeted integration into stem cells
|
|
US8772008B2
(en)
|
2009-05-18 |
2014-07-08 |
Sangamo Biosciences, Inc. |
Methods and compositions for increasing nuclease activity
|
|
AU2010266705B2
(en)
|
2009-06-30 |
2014-06-05 |
Sangamo Therapeutics, Inc. |
Rapid screening of biologically active nucleases and isolation of nuclease-modified cells
|
|
EP2461819A4
(en)
|
2009-07-28 |
2013-07-31 |
Sangamo Biosciences Inc |
Methods and compositions for treating trinucleotide repeat disorders
|
|
DK2462230T3
(en)
|
2009-08-03 |
2015-10-19 |
Recombinetics Inc |
METHODS AND COMPOSITIONS FOR TARGETED RE-MODIFICATION
|
|
KR20120038020A
(en)
|
2009-08-11 |
2012-04-20 |
상가모 바이오사이언스 인코포레이티드 |
Organisms homozygous for targeted modification
|
|
US9476060B2
(en)
|
2009-10-21 |
2016-10-25 |
Danziger Innovations Ltd. |
Generating genotypic variations in plant genomes by gamete infection
|
|
AR078740A1
(en)
|
2009-10-22 |
2011-11-30 |
Dow Agrosciences Llc |
PROTEINS WITH ZINC FINGERS DESIGNED BY ENGINEERING THAT HAVE THE OBJECTIVE OF VEGETABLE GENES INCLUDED IN THE BIOSINTESIS OF FATTY ACIDS
|
|
US8956828B2
(en)
|
2009-11-10 |
2015-02-17 |
Sangamo Biosciences, Inc. |
Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
|
|
CA2782014C
(en)
|
2009-11-27 |
2021-08-31 |
Basf Plant Science Company Gmbh |
Optimized endonucleases and uses thereof
|
|
UA118328C2
(en)
|
2010-01-22 |
2019-01-10 |
Дау Агросайєнсіз Ллс |
Targeted gemomic alteration
|
|
PT2534173T
(en)
|
2010-02-08 |
2019-10-31 |
Sangamo Therapeutics Inc |
Engineered cleavage half-domains
|
|
EP2660318A1
(en)
|
2010-02-09 |
2013-11-06 |
Sangamo BioSciences, Inc. |
Targeted genomic modification with partially single-stranded donor molecules
|
|
CA2796600C
(en)
|
2010-04-26 |
2019-08-13 |
Sangamo Biosciences, Inc. |
Genome editing of a rosa locus using zinc-finger nucleases
|
|
LT2566972T
(en)
|
2010-05-03 |
2020-03-10 |
Sangamo Therapeutics, Inc. |
Compositions for linking zinc finger modules
|
|
EP3156062A1
(en)
|
2010-05-17 |
2017-04-19 |
Sangamo BioSciences, Inc. |
Novel dna-binding proteins and uses thereof
|
|
WO2012012667A2
(en)
|
2010-07-21 |
2012-01-26 |
Sangamo Biosciences, Inc. |
Methods and compositions for modification of a hla locus
|
|
EP2622090B1
(en)
|
2010-09-27 |
2019-06-19 |
Sangamo Therapeutics, Inc. |
Compositions for inhibiting viral entry into cells
|
|
ES2562421T3
(en)
|
2010-10-12 |
2016-03-04 |
The Children's Hospital Of Philadelphia |
Methods and compositions to treat hemophilia B
|
|
WO2012094132A1
(en)
|
2011-01-05 |
2012-07-12 |
Sangamo Biosciences, Inc. |
Methods and compositions for gene correction
|
|
WO2012139045A1
(en)
|
2011-04-08 |
2012-10-11 |
Gilead Biologics, Inc. |
Methods and compositions for normalization of tumor vasculature by inhibition of loxl2
|
|
AU2012286901B2
(en)
|
2011-07-25 |
2016-10-27 |
Sangamo Therapeutics, Inc. |
Methods and compositions for alteration of a cystic fibrosis transmembrane conductance regulator (CFTR) gene
|
|
IL293650B2
(en)
|
2011-09-21 |
2024-10-01 |
Sangamo Therapeutics Inc |
Methods and preparations for regulating transgene expression
|
|
JP6188703B2
(en)
|
2011-10-27 |
2017-08-30 |
サンガモ セラピューティクス， インコーポレイテッド |
Methods and compositions for modifying the HPRT locus
|
|
JP6144691B2
(en)
|
2011-11-16 |
2017-06-07 |
サンガモ セラピューティクス， インコーポレイテッド |
Modified DNA binding proteins and uses thereof
|
|
HK1199200A1
(en)
|
2012-01-27 |
2015-06-26 |
Sanbio, Inc. |
Methods and compositions for modulating angiogenesis and vasculogenesis
|
|
MX374399B
(en)
|
2012-02-29 |
2025-03-06 |
Sangamo Biosciences Inc |
COMPOSITIONS AND THEIR USES FOR TREATING AND PREVENTING HUNTINGTON'S DISEASE.
|
|
WO2013158309A2
(en)
|
2012-04-18 |
2013-10-24 |
The Board Of Trustees Of The Leland Stanford Junior University |
Non-disruptive gene targeting
|
|
WO2013163628A2
(en)
|
2012-04-27 |
2013-10-31 |
Duke University |
Genetic correction of mutated genes
|
|
RU2658437C2
(en)
|
2012-05-02 |
2018-06-21 |
ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи |
Targeted modification of malate dehydrogenase
|
|
JP6559063B2
(en)
|
2012-05-07 |
2019-08-14 |
サンガモ セラピューティクス， インコーポレイテッド |
Methods and compositions for nuclease-mediated targeted integration of transgenes
|
|
US11120889B2
(en)
|
2012-05-09 |
2021-09-14 |
Georgia Tech Research Corporation |
Method for synthesizing a nuclease with reduced off-site cleavage
|
|
CA2878037C
(en)
|
2012-07-11 |
2021-08-31 |
Sangamo Biosciences, Inc. |
Methods and compositions for delivery of biologics
|
|
AU2013289206B2
(en)
|
2012-07-11 |
2018-08-09 |
Sangamo Therapeutics, Inc. |
Methods and compositions for the treatment of lysosomal storage diseases
|
|
US10648001B2
(en)
|
2012-07-11 |
2020-05-12 |
Sangamo Therapeutics, Inc. |
Method of treating mucopolysaccharidosis type I or II
|
|
ES2812599T3
(en)
|
2012-08-29 |
2021-03-17 |
Sangamo Therapeutics Inc |
Procedures and compositions for the treatment of a genetic condition
|
|
UA118090C2
(en)
|
2012-09-07 |
2018-11-26 |
ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі |
Fad2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
|
|
JP6775953B2
(en)
|
2012-09-07 |
2020-10-28 |
ダウ アグロサイエンシィズ エルエルシー |
FAD3 performance locus and corresponding target site-specific binding proteins capable of inducing targeted cleavage
|
|
UA119135C2
(en)
|
2012-09-07 |
2019-05-10 |
ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі |
Engineered transgene integration platform (etip) for gene targeting and trait stacking
|
|
CA2886684C
(en)
|
2012-10-10 |
2023-09-19 |
Sangamo Biosciences, Inc. |
T cell modifying compounds and uses thereof
|
|
JP2016500254A
(en)
|
2012-12-05 |
2016-01-12 |
サンガモ バイオサイエンシーズ， インコーポレイテッド |
Methods and compositions for the regulation of metabolic diseases
|
|
EP2931901A1
(en)
|
2012-12-13 |
2015-10-21 |
Dow AgroSciences LLC |
Precision gene targeting to a particular locus in maize
|
|
CA2901676C
(en)
|
2013-02-25 |
2023-08-22 |
Sangamo Biosciences, Inc. |
Methods and compositions for enhancing nuclease-mediated gene disruption
|
|
US9828582B2
(en)
|
2013-03-19 |
2017-11-28 |
Duke University |
Compositions and methods for the induction and tuning of gene expression
|
|
AU2014235968B2
(en)
|
2013-03-21 |
2018-05-24 |
Ospedale San Raffaele Srl |
Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
|
|
UA121197C2
(en)
|
2013-04-05 |
2020-04-27 |
Доу Агросайенсіс Ллс |
Methods and compositions for integration of an exogenous sequence within the genome of plants
|
|
WO2014186435A2
(en)
|
2013-05-14 |
2014-11-20 |
University Of Georgia Research Foundation, Inc. |
Compositions and methods for reducing neointima formation
|
|
EP3730615A3
(en)
|
2013-05-15 |
2020-12-09 |
Sangamo Therapeutics, Inc. |
Methods and compositions for treatment of a genetic condition
|
|
EP3591045B1
(en)
|
2013-08-28 |
2024-07-17 |
Sangamo Therapeutics, Inc. |
Compositions for linking dna-binding domains and cleavage domains
|
|
WO2015057976A1
(en)
|
2013-10-17 |
2015-04-23 |
Sangamo Biosciences, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells
|
|
CN116836957A
(en)
|
2013-10-17 |
2023-10-03 |
桑格摩生物科学股份有限公司 |
Delivery methods and compositions for nuclease-mediated genome engineering
|
|
MX358066B
(en)
|
2013-11-04 |
2018-08-03 |
Dow Agrosciences Llc |
Optimal soybean loci.
|
|
CA2928855A1
(en)
|
2013-11-04 |
2015-05-07 |
Dow Agrosciences Llc |
Optimal maize loci
|
|
MX362066B
(en)
|
2013-11-04 |
2019-01-07 |
Dow Agrosciences Llc |
Optimal soybean loci.
|
|
US10273493B2
(en)
|
2013-11-04 |
2019-04-30 |
Dow Agrosciences Llc |
Optimal maize loci
|
|
WO2015070212A1
(en)
|
2013-11-11 |
2015-05-14 |
Sangamo Biosciences, Inc. |
Methods and compositions for treating huntington's disease
|
|
SI3068881T1
(en)
|
2013-11-13 |
2019-05-31 |
Children's Medical Center Corporation |
Nuclease-mediated regulation of gene expression
|
|
US9932607B2
(en)
|
2013-11-15 |
2018-04-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Site-specific integration of transgenes into human cells
|
|
CN105874071B
(en)
|
2013-12-09 |
2020-04-14 |
桑格摩生物科学股份有限公司 |
Methods and compositions for genome engineering
|
|
US10774338B2
(en)
|
2014-01-16 |
2020-09-15 |
The Regents Of The University Of California |
Generation of heritable chimeric plant traits
|
|
HRP20201038T1
(en)
|
2014-02-03 |
2020-10-16 |
Sangamo Therapeutics, Inc. |
PROCEDURES AND PREPARATIONS FOR THE TREATMENT OF BETA THALASEMIA
|
|
JP6606088B2
(en)
|
2014-02-24 |
2019-11-13 |
サンガモ セラピューティクス， インコーポレイテッド |
Methods and compositions for nuclease-mediated targeted integration
|
|
TW201538518A
(en)
|
2014-02-28 |
2015-10-16 |
Dow Agrosciences Llc |
Root specific expression conferred by chimeric gene regulatory elements
|
|
AU2015231353B2
(en)
|
2014-03-18 |
2020-11-05 |
Sangamo Therapeutics, Inc. |
Methods and compositions for regulation of zinc finger protein expression
|
|
EP3119895B1
(en)
|
2014-03-21 |
2023-12-20 |
The Board of Trustees of the Leland Stanford Junior University |
Genome editing without nucleases
|
|
US10507232B2
(en)
|
2014-04-02 |
2019-12-17 |
University Of Florida Research Foundation, Incorporated |
Materials and methods for the treatment of latent viral infection
|
|
US9522936B2
(en)
|
2014-04-24 |
2016-12-20 |
Sangamo Biosciences, Inc. |
Engineered transcription activator like effector (TALE) proteins
|
|
BR112016025849A2
(en)
|
2014-05-08 |
2017-10-17 |
Chdi Foundation Inc |
methods and compositions for the treatment of huntington's disease
|
|
US10272019B2
(en)
|
2014-05-09 |
2019-04-30 |
Yale University |
Topical formulation of hyperbranched polyglycerol-coated particles thereof
|
|
US11918695B2
(en)
|
2014-05-09 |
2024-03-05 |
Yale University |
Topical formulation of hyperbranched polymer-coated particles
|
|
US9574211B2
(en)
|
2014-05-13 |
2017-02-21 |
Sangamo Biosciences, Inc. |
Methods and compositions for prevention or treatment of a disease
|
|
EP3152319A4
(en)
|
2014-06-05 |
2017-12-27 |
Sangamo BioSciences, Inc. |
Methods and compositions for nuclease design
|
|
WO2016005449A1
(en)
|
2014-07-08 |
2016-01-14 |
Vib Vzw |
Means and methods to increase plant yield
|
|
MX2017000555A
(en)
|
2014-07-14 |
2017-08-10 |
Univ Washington State |
Nanos knock-out that ablates germline cells.
|
|
CA2954414A1
(en)
|
2014-07-15 |
2016-01-21 |
Juno Therapeutics, Inc. |
Engineered cells for adoptive cell therapy
|
|
US11278572B2
(en)
|
2014-07-18 |
2022-03-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Reducing CXCR4 expression and/or function to enhance engraftment of hematopoietic stem cells
|
|
WO2016014837A1
(en)
|
2014-07-25 |
2016-01-28 |
Sangamo Biosciences, Inc. |
Gene editing for hiv gene therapy
|
|
WO2016014794A1
(en)
|
2014-07-25 |
2016-01-28 |
Sangamo Biosciences, Inc. |
Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells
|
|
US9616090B2
(en)
|
2014-07-30 |
2017-04-11 |
Sangamo Biosciences, Inc. |
Gene correction of SCID-related genes in hematopoietic stem and progenitor cells
|
|
JP6722176B2
(en)
|
2014-09-16 |
2020-07-15 |
サンガモ セラピューティクス， インコーポレイテッド |
Methods and compositions for nuclease-mediated genomic engineering and correction in hematopoietic stem cells
|
|
US10889834B2
(en)
|
2014-12-15 |
2021-01-12 |
Sangamo Therapeutics, Inc. |
Methods and compositions for enhancing targeted transgene integration
|
|
WO2016118726A2
(en)
|
2015-01-21 |
2016-07-28 |
Sangamo Biosciences, Inc. |
Methods and compositions for identification of highly specific nucleases
|
|
EP3250680A4
(en)
|
2015-01-26 |
2018-12-05 |
Fate Therapeutics, Inc. |
Methods and compositions for inducing hematopoietic cell differentiation
|
|
US10676726B2
(en)
|
2015-02-09 |
2020-06-09 |
Duke University |
Compositions and methods for epigenome editing
|
|
ES2959608T3
(en)
|
2015-04-03 |
2024-02-27 |
Dana Farber Cancer Inst Inc |
Composition and editing methods of the B cell genome
|
|
BR112017021703B1
(en)
|
2015-04-15 |
2023-11-28 |
Corteva Agriscience Llc |
PLANT PROMOTER FOR TRANSGENE EXPRESSION
|
|
KR20170136549A
(en)
|
2015-04-15 |
2017-12-11 |
다우 아그로사이언시즈 엘엘씨 |
Plant promoters for transgen expression
|
|
CN108026566A
(en)
|
2015-05-04 |
2018-05-11 |
特拉维夫大学拉莫特有限公司 |
For making the method and kit of DNA fragmentation
|
|
US10179918B2
(en)
|
2015-05-07 |
2019-01-15 |
Sangamo Therapeutics, Inc. |
Methods and compositions for increasing transgene activity
|
|
EP3294866A4
(en)
|
2015-05-12 |
2018-12-05 |
Sangamo Therapeutics, Inc. |
Nuclease-mediated regulation of gene expression
|
|
EP3303586A1
(en)
|
2015-05-29 |
2018-04-11 |
Juno Therapeutics, Inc. |
Composition and methods for regulating inhibitory interactions in genetically engineered cells
|
|
US9957501B2
(en)
|
2015-06-18 |
2018-05-01 |
Sangamo Therapeutics, Inc. |
Nuclease-mediated regulation of gene expression
|
|
AU2016291778B2
(en)
|
2015-07-13 |
2021-05-06 |
Sangamo Therapeutics, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
|
MA42895A
(en)
|
2015-07-15 |
2018-05-23 |
Juno Therapeutics Inc |
MODIFIED CELLS FOR ADOPTIVE CELL THERAPY
|
|
BR112018002417A2
(en)
|
2015-08-06 |
2018-09-18 |
Univ Missouri |
non-human animal or descendant thereof or an animal cell, swine animal, descendant or cell, cell, descendant, reproduction method, animal population, method for increasing an animal resistance, nucleic acid molecule, nucleic acid and nucleic acid isolated
|
|
TW201718862A
(en)
|
2015-09-22 |
2017-06-01 |
Dow Agrosciences Llc |
Plant promoter and 3' UTR for transgene expression
|
|
TW201718861A
(en)
|
2015-09-22 |
2017-06-01 |
道禮責任有限公司 |
Plant promoter and 3'UTR for transgene expression
|
|
ES3032775T3
(en)
|
2015-09-23 |
2025-07-24 |
Sangamo Therapeutics Inc |
Htt repressors and uses thereof
|
|
WO2017066497A2
(en)
|
2015-10-13 |
2017-04-20 |
Duke University |
Genome engineering with type i crispr systems in eukaryotic cells
|
|
EP3365451B1
(en)
|
2015-10-22 |
2020-06-24 |
Dow Agrosciences LLC |
Plant promoter for transgene expression
|
|
EP3371314B1
(en)
|
2015-11-04 |
2023-07-05 |
Fate Therapeutics, Inc. |
Genomic engineering of pluripotent cells
|
|
US20170121726A1
(en)
|
2015-11-04 |
2017-05-04 |
Dow Agrosciences Llc |
Plant promoter for transgene expression
|
|
AU2016348342B2
(en)
|
2015-11-04 |
2023-07-06 |
Fate Therapeutics, Inc. |
Methods and compositions for inducing hematopoietic cell differentiation
|
|
WO2017091512A1
(en)
|
2015-11-23 |
2017-06-01 |
Sangamo Biosciences, Inc. |
Methods and compositions for engineering immunity
|
|
KR20250044471A
(en)
|
2015-11-30 |
2025-03-31 |
듀크 유니버시티 |
Therapeutic targets for the correction of the human dystrophin gene by gene editing and methods of use
|
|
CN108778297B
(en)
|
2015-12-18 |
2024-02-09 |
桑格摩生物治疗股份有限公司 |
Targeted destruction of T cell receptors
|
|
SG11201805157TA
(en)
|
2015-12-18 |
2018-07-30 |
Sangamo Therapeutics Inc |
Targeted disruption of the mhc cell receptor
|
|
AU2017207818B2
(en)
|
2016-01-15 |
2024-03-28 |
Regents Of The University Of Minnesota |
Methods and compositions for the treatment of neurologic disease
|
|
EP3411056A4
(en)
|
2016-02-02 |
2019-10-02 |
Sangamo Therapeutics, Inc. |
COMPOSITIONS FOR BINDING DNA BINDING DOMAINS AND CLEAVAGE DOMAINS
|
|
CA3014792A1
(en)
|
2016-02-16 |
2017-08-24 |
Carnegie Mellon University |
Compositions for enhancing targeted gene editing and methods of use thereof
|
|
US20200308590A1
(en)
|
2016-02-16 |
2020-10-01 |
Yale University |
Compositions and methods for treatment of cystic fibrosis
|
|
CA3016504A1
(en)
|
2016-03-23 |
2017-09-28 |
Dana-Farber Cancer Institute, Inc. |
Methods for enhancing the efficiency of gene editing
|
|
WO2017173453A1
(en)
|
2016-04-01 |
2017-10-05 |
The Brigham And Women's Hospital, Inc. |
Stimuli-responsive nanoparticles for biomedical applications
|
|
WO2017180915A2
(en)
|
2016-04-13 |
2017-10-19 |
Duke University |
Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use
|
|
US11514331B2
(en)
|
2016-04-27 |
2022-11-29 |
Massachusetts Institute Of Technology |
Sequence-controlled polymer random access memory storage
|
|
WO2017189870A1
(en)
|
2016-04-27 |
2017-11-02 |
Massachusetts Institute Of Technology |
Stable nanoscale nucleic acid assemblies and methods thereof
|
|
CN110291402B
(en)
|
2016-06-27 |
2023-09-01 |
朱诺治疗学股份有限公司 |
Methods of identifying peptide epitopes, molecules that bind such epitopes, and related uses
|
|
MA45491A
(en)
|
2016-06-27 |
2019-05-01 |
Juno Therapeutics Inc |
CMH-E RESTRICTED EPITOPES, BINDING MOLECULES AND RELATED METHODS AND USES
|
|
ES2938210T3
(en)
|
2016-07-13 |
2023-04-05 |
Vertex Pharma |
Methods, compositions and kits to increase the efficiency of genome editing
|
|
JP7490211B2
(en)
|
2016-07-19 |
2024-05-27 |
デューク ユニバーシティ |
Therapeutic Applications of CPF1-Based Genome Editing
|
|
CN109789128A
(en)
|
2016-07-27 |
2019-05-21 |
凯斯西储大学 |
Compounds and methods for promoting myelination
|
|
EP3497213B1
(en)
|
2016-08-09 |
2023-10-18 |
Vib Vzw |
Cellulose synthase inhibitors and mutant plants
|
|
BR112019003327A2
(en)
|
2016-08-24 |
2019-07-02 |
Sangamo Therapeutics, Inc. |
specific target engineered nucleases
|
|
DK3504229T3
(en)
|
2016-08-24 |
2021-12-20 |
Sangamo Therapeutics Inc |
REGULATION OF GENEPRESSION USING MANIPULATED NUCLEASES
|
|
JP7256739B2
(en)
|
2016-09-07 |
2023-04-12 |
サンガモ セラピューティクス， インコーポレイテッド |
Modulation of liver genes
|
|
CN109996436B
(en)
|
2016-10-03 |
2023-09-29 |
科迪华农业科技有限责任公司 |
Plant promoters for transgene expression
|
|
EP3519433A1
(en)
|
2016-10-03 |
2019-08-07 |
Juno Therapeutics, Inc. |
Hpv-specific binding molecules
|
|
EP3519574B1
(en)
|
2016-10-03 |
2022-01-19 |
Corteva Agriscience LLC |
Plant promoter for transgene expression
|
|
WO2018067826A1
(en)
|
2016-10-05 |
2018-04-12 |
Cellular Dynamics International, Inc. |
Generating mature lineages from induced pluripotent stem cells with mecp2 disruption
|
|
MA50839A
(en)
|
2016-10-13 |
2019-08-21 |
Juno Therapeutics Inc |
METHODS AND COMPOSITIONS OF IMMUNOTHERAPY INVOLVING MODULATORS OF THE TRYPTOPHAN METABOLIC PATHWAY
|
|
JP7042263B2
(en)
|
2016-10-20 |
2022-03-25 |
サンガモ セラピューティクス， インコーポレイテッド |
Methods and compositions for the treatment of Fabry disease
|
|
US11766400B2
(en)
|
2016-10-24 |
2023-09-26 |
Yale University |
Biodegradable contraceptive implants
|
|
AU2017347928A1
(en)
|
2016-10-31 |
2019-05-09 |
Sangamo Therapeutics, Inc. |
Gene correction of scid-related genes in hematopoietic stem and progenitor cells
|
|
US11504389B2
(en)
|
2016-12-01 |
2022-11-22 |
Sangamo Therapeutics, Inc. |
Tau modulators and methods and compositions for delivery thereof
|
|
US11793833B2
(en)
|
2016-12-02 |
2023-10-24 |
Juno Therapeutics, Inc. |
Engineered B cells and related compositions and methods
|
|
CA3045338A1
(en)
|
2016-12-05 |
2018-06-14 |
Juno Therapeutics, Inc. |
Production of engineered cells for adoptive cell therapy
|
|
ES2968892T3
(en)
|
2016-12-08 |
2024-05-14 |
Univ Case Western Reserve |
Methods and compositions to increase the production of functional myelin
|
|
US20200085758A1
(en)
|
2016-12-16 |
2020-03-19 |
The Brigham And Women's Hospital, Inc. |
Co-delivery of nucleic acids for simultaneous suppression and expression of target genes
|
|
CA3054031A1
(en)
|
2017-02-22 |
2018-08-30 |
Crispr Therapeutics Ag |
Compositions and methods for gene editing
|
|
WO2018187493A1
(en)
|
2017-04-04 |
2018-10-11 |
Yale University |
Compositions and methods for in utero delivery
|
|
SG11201906948UA
(en)
|
2017-04-20 |
2019-08-27 |
Univ Oregon Health & Science |
Human gene correction
|
|
WO2018204469A2
(en)
|
2017-05-03 |
2018-11-08 |
Sangamo Therapeutics, Inc. |
Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (cftr) gene
|
|
US11512287B2
(en)
|
2017-06-16 |
2022-11-29 |
Sangamo Therapeutics, Inc. |
Targeted disruption of T cell and/or HLA receptors
|
|
EP3654763A4
(en)
|
2017-06-28 |
2021-06-09 |
Dow Agrosciences LLC |
PLANT PROMOTER FOR TRANSGENIC EXPRESSION
|
|
KR102669445B1
(en)
|
2017-08-08 |
2024-05-28 |
상가모 테라퓨틱스, 인코포레이티드 |
Chimeric antigen receptor-mediated cell targeting
|
|
EP3692063A1
(en)
|
2017-10-03 |
2020-08-12 |
Juno Therapeutics, Inc. |
Hpv-specific binding molecules
|
|
WO2019089982A1
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Method of assessing activity of recombinant antigen receptors
|
|
BR112020008568A2
(en)
|
2017-11-09 |
2020-10-06 |
Sangamo Therapeutics, Inc. |
genetic modification of protein gene containing cytokine-inducible sh2 (cish)
|
|
WO2019094928A1
(en)
|
2017-11-10 |
2019-05-16 |
Massachusetts Institute Of Technology |
Microbial production of pure single stranded nucleic acids
|
|
EP3713644B1
(en)
|
2017-11-20 |
2024-08-07 |
University of Georgia Research Foundation, Inc. |
Compositions and methods for modulating hif-2a to improve muscle generation and repair
|
|
BR112020010883A2
(en)
|
2017-12-01 |
2020-11-10 |
Encoded Therapeutics, Inc. |
engineered dna binding proteins
|
|
US11459577B2
(en)
|
2017-12-18 |
2022-10-04 |
Syngenta Participations Ag |
Targeted insertion sites in the maize genome
|
|
EP3728563B1
(en)
|
2017-12-22 |
2025-06-18 |
Fate Therapeutics, Inc. |
Enhanced immune effector cells and use thereof
|
|
KR20200110685A
(en)
|
2018-01-17 |
2020-09-24 |
버텍스 파마슈티칼스 인코포레이티드 |
DNA-PK inhibitor
|
|
AU2019209290B2
(en)
|
2018-01-17 |
2024-03-07 |
Vertex Pharmaceuticals Incorporated |
DNA-PK inhibitors
|
|
MA51623A
(en)
|
2018-01-17 |
2021-04-14 |
Vertex Pharma |
QUINOXALINONE COMPOUNDS, COMPOSITIONS, METHODS AND KITS FOR INCREASING GENOME EDITING EFFICIENCY
|
|
WO2019144061A1
(en)
|
2018-01-19 |
2019-07-25 |
Duke University |
Genome engineering with crispr-cas systems in eukaryotes
|
|
KR20200118468A
(en)
|
2018-02-08 |
2020-10-15 |
상가모 테라퓨틱스, 인코포레이티드 |
Engineered target specific nuclease
|
|
US20210024959A1
(en)
|
2018-03-29 |
2021-01-28 |
Fate Therapeutics, Inc. |
Engineered immune effector cells and use thereof
|
|
BR112020020245A2
(en)
|
2018-04-05 |
2021-04-06 |
Editas Medicine, Inc. |
METHODS OF PRODUCING CELLS EXPRESSING A RECOMBINANT RECEIVER AND RELATED COMPOSITIONS
|
|
MX2020010461A
(en)
|
2018-04-05 |
2021-01-15 |
Juno Therapeutics Inc |
T cells expressing a recombinant receptor, related polynucleotides and methods.
|
|
KR102764123B1
(en)
|
2018-04-05 |
2025-02-05 |
주노 쎄러퓨티크스 인코퍼레이티드 |
T cell receptor and engineered cells expressing it
|
|
CN112313246B
(en)
|
2018-04-18 |
2025-05-13 |
桑格摩生物治疗股份有限公司 |
Zinc finger protein composition for regulating huntingtin protein (HTT)
|
|
BR112020022879A2
(en)
|
2018-05-11 |
2021-02-23 |
Crispr Therapeutics Ag |
methods and compositions for cancer treatment
|
|
US11690921B2
(en)
|
2018-05-18 |
2023-07-04 |
Sangamo Therapeutics, Inc. |
Delivery of target specific nucleases
|
|
GB201809273D0
(en)
|
2018-06-06 |
2018-07-25 |
Vib Vzw |
Novel mutant plant cinnamoyl-coa reductase proteins
|
|
US11827892B2
(en)
|
2018-06-07 |
2023-11-28 |
The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) |
Nucleic acid constructs and methods of using same
|
|
WO2019234750A1
(en)
|
2018-06-07 |
2019-12-12 |
The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) |
Methods of regenerating and transforming cannabis
|
|
WO2020028617A1
(en)
|
2018-08-01 |
2020-02-06 |
University Of Georgia Research Foundation, Inc. |
Compositions and methods for improving embryo development
|
|
WO2020041249A1
(en)
|
2018-08-23 |
2020-02-27 |
Sangamo Therapeutics, Inc. |
Engineered target specific base editors
|
|
MX2021002266A
(en)
|
2018-08-31 |
2021-05-27 |
Univ Yale |
Compositions and methods for enhancing triplex and nuclease-based gene editing.
|
|
MX2021002265A
(en)
|
2018-08-31 |
2021-05-27 |
Univ Yale |
Compositions and methods for enhancing donor oligonucleotide-base d gene editing.
|
|
JP2022500052A
(en)
|
2018-09-18 |
2022-01-04 |
サンガモ セラピューティクス， インコーポレイテッド |
Programmed cell death 1 (PD1) specific nuclease
|
|
EP3852911B1
(en)
|
2018-09-21 |
2025-01-22 |
Acuitas Therapeutics, Inc. |
Systems and methods for manufacturing lipid nanoparticles and liposomes
|
|
EP3860618B1
(en)
|
2018-10-02 |
2026-02-04 |
Sangamo Therapeutics, Inc. |
Compositions for treating tauopathy
|
|
KR20210089707A
(en)
|
2018-11-07 |
2021-07-16 |
크리스퍼 테라퓨틱스 아게 |
Anti-LIV1 Immune Cell Cancer Therapy
|
|
CA3118830A1
(en)
|
2018-11-07 |
2020-05-14 |
Crispr Therapeutics Ag |
Anti-ptk7 immune cell cancer therapy
|
|
CA3118816A1
(en)
|
2018-11-07 |
2020-05-14 |
Crispr Therapeutics Ag |
Anti-cd33 immune cell cancer therapy
|
|
WO2020112195A1
(en)
|
2018-11-30 |
2020-06-04 |
Yale University |
Compositions, technologies and methods of using plerixafor to enhance gene editing
|
|
CA3121128A1
(en)
|
2018-12-02 |
2020-06-11 |
Fate Therapeutics, Inc. |
Immunotherapies using enhanced ipsc derived effector cells
|
|
AU2019391114B2
(en)
|
2018-12-05 |
2026-01-29 |
Vertex Pharmaceuticals Incorporated |
Gene-editing systems for editing a cystic fibrosis transmembrane regulator (CFTR) gene
|
|
GB201820109D0
(en)
|
2018-12-11 |
2019-01-23 |
Vib Vzw |
Plants with a lignin trait and udp-glycosyltransferase mutation
|
|
EP4450487A3
(en)
|
2019-01-11 |
2024-12-25 |
Acuitas Therapeutics, Inc. |
Lipids for lipid nanoparticle delivery of active agents
|
|
US12156877B1
(en)
|
2019-01-15 |
2024-12-03 |
The Regents Of The University Of California |
Methods of treating conditions related to a thiamine deficiency, a thiamine-dependent enzyme, or an associated cofactor
|
|
US11419932B2
(en)
|
2019-01-24 |
2022-08-23 |
Massachusetts Institute Of Technology |
Nucleic acid nanostructure platform for antigen presentation and vaccine formulations formed therefrom
|
|
WO2020162978A1
(en)
|
2019-02-06 |
2020-08-13 |
Sangamo Therapeutics, Inc. |
Method for the treatment of mucopolysaccharidosis type i
|
|
KR20210148106A
(en)
|
2019-03-08 |
2021-12-07 |
옵시디안 테라퓨틱스, 인크. |
CD40L compositions and methods for tunable modulation
|
|
KR20210146986A
(en)
|
2019-04-02 |
2021-12-06 |
상가모 테라퓨틱스, 인코포레이티드 |
Methods of treating beta-thalassemia
|
|
TW202521561A
(en)
|
2019-04-23 |
2025-06-01 |
美商聖加莫治療股份有限公司 |
Modulators of chromosome 9 open reading frame 72 gene expression and uses thereof
|
|
MX2021013219A
(en)
|
2019-05-01 |
2022-02-17 |
Juno Therapeutics Inc |
CELLS EXPRESSING A RECOMBINANT RECEPTOR OF A MODIFIED TGFBR2 LOCUS, RELATED POLYNUCLEOTIDES AND METHODS.
|
|
SG11202111372VA
(en)
|
2019-05-01 |
2021-11-29 |
Juno Therapeutics Inc |
Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods
|
|
SG11202113048SA
(en)
|
2019-05-29 |
2021-12-30 |
Encoded Therapeutics Inc |
Compositions and methods for selective gene regulation
|
|
US11905532B2
(en)
|
2019-06-25 |
2024-02-20 |
Massachusetts Institute Of Technology |
Compositions and methods for molecular memory storage and retrieval
|
|
BR112021026382A2
(en)
|
2019-06-27 |
2022-02-08 |
Crispr Therapeutics Ag |
Use of chimeric antigen receptor t cells and nk cell inhibitors for cancer treatment
|
|
WO2021011919A1
(en)
|
2019-07-17 |
2021-01-21 |
Fate Therapeutics, Inc. |
Immune effector cell engineering and use thereof
|
|
US20220267732A1
(en)
|
2019-08-01 |
2022-08-25 |
Sana Biotechnology, Inc. |
Dux4 expressing cells and uses thereof
|
|
AU2020336302A1
(en)
|
2019-08-23 |
2022-03-03 |
Sana Biotechnology, Inc. |
CD24 expressing cells and uses thereof
|
|
AU2020336992A1
(en)
|
2019-08-30 |
2022-04-14 |
Yale University |
Compositions and methods for delivery of nucleic acids to cells
|
|
US12344656B2
(en)
|
2019-09-06 |
2025-07-01 |
Crispr Therapeutics Ag |
Genetically engineered T cells having improved persistence in culture
|
|
EP4041271A1
(en)
|
2019-10-02 |
2022-08-17 |
Sangamo Therapeutics, Inc. |
Zinc finger protein transcription factors for treatment of prion disease
|
|
US20220324928A1
(en)
|
2019-10-02 |
2022-10-13 |
Sangamo Therapeutics, Inc. |
Zinc Finger Protein Transcription Factors for Repressing Alpha-Synuclein Expression
|
|
US20210130828A1
(en)
|
2019-11-01 |
2021-05-06 |
Sangamo Therapeutics, Inc. |
Gin recombinase variants
|
|
TW202130812A
(en)
|
2019-11-01 |
2021-08-16 |
美商聖加莫治療股份有限公司 |
Compositions and methods for genome engineering
|
|
MX2022008415A
(en)
|
2020-01-08 |
2022-08-08 |
Obsidian Therapeutics Inc |
Compositions and methods for tunable regulation of transcription.
|
|
KR20220131273A
(en)
|
2020-01-22 |
2022-09-27 |
상가모 테라퓨틱스, 인코포레이티드 |
Zinc Finger Protein Transcription Factor to Inhibit Tau Expression
|
|
EP4097124A1
(en)
|
2020-01-28 |
2022-12-07 |
The Broad Institute Inc. |
Base editors, compositions, and methods for modifying the mitochondrial genome
|
|
KR20220158046A
(en)
|
2020-03-25 |
2022-11-29 |
사나 바이오테크놀로지, 인크. |
Immunocompromised Neuronal Cells for Treatment of Nervous System Disorders and Conditions
|
|
US12534744B2
(en)
|
2020-05-06 |
2026-01-27 |
Cellectis S.A. |
Methods to genetically modify cells for delivery of therapeutic proteins
|
|
AU2021268253A1
(en)
|
2020-05-06 |
2022-12-08 |
Cellectis S.A. |
Methods for targeted insertion of exogenous sequences in cellular genomes
|
|
CN115835873A
(en)
|
2020-05-13 |
2023-03-21 |
朱诺治疗学股份有限公司 |
Method for producing donor batch cells expressing recombinant receptors
|
|
US20230190871A1
(en)
|
2020-05-20 |
2023-06-22 |
Sana Biotechnology, Inc. |
Methods and compositions for treatment of viral infections
|
|
WO2021247836A1
(en)
|
2020-06-03 |
2021-12-09 |
Board Of Regents, The University Of Texas System |
Methods for targeting shp-2 to overcome resistance
|
|
BR112022025806A2
(en)
|
2020-06-19 |
2023-03-07 |
Fate Therapeutics Inc |
IPSC-DERIVED EFFECTOR CELL TYPE COMBINATION FOR USE IN IMMUNOTHERAPY
|
|
JP2023531531A
(en)
|
2020-06-26 |
2023-07-24 |
ジュノ セラピューティクス ゲーエムベーハー |
Engineered T Cells Conditionally Expressing Recombinant Receptors, Related Polynucleotides, and Methods
|
|
EP4182297B1
(en)
|
2020-07-16 |
2025-09-03 |
Acuitas Therapeutics, Inc. |
Cationic lipids for use in lipid nanoparticles
|
|
KR20230074718A
(en)
|
2020-08-13 |
2023-05-31 |
사나 바이오테크놀로지, 인크. |
Methods of treating patients sensitized with hypoimmunogenic cells and related methods and compositions
|
|
EP4501951A3
(en)
|
2020-08-25 |
2025-04-30 |
Kite Pharma, Inc. |
T cells with improved functionality
|
|
AU2021331785A1
(en)
|
2020-08-31 |
2023-03-30 |
Gennao Bio, Inc. |
Compositions and methods for delivery of nucleic acids to cells
|
|
CA3192280A1
(en)
|
2020-09-23 |
2022-03-31 |
Mary-Lee Dequeant |
Genetically engineered t cells with regnase-1 and/or tgfbrii disruption have improved functionality and persistence
|
|
US20240043829A1
(en)
|
2020-09-25 |
2024-02-08 |
Sangamo Therapeutics, Inc. |
Zinc finger fusion proteins for nucleobase editing
|
|
CN116917335A
(en)
|
2020-10-02 |
2023-10-20 |
桑格摩生物治疗股份有限公司 |
Novel zinc finger protein transcription factor for repressing α-synuclein (SYNUCLEIN) expression
|
|
JP2023549780A
(en)
|
2020-11-04 |
2023-11-29 |
ジュノー セラピューティクス インコーポレイテッド |
Cells expressing chimeric receptors from engineered invariant CD3 immunoglobulin superfamily chain loci and related polynucleotides and methods
|
|
CA3200855A1
(en)
|
2020-11-16 |
2022-05-19 |
Pig Improvement Company Uk Limited |
Influenza a-resistant animals having edited anp32 genes
|
|
EP4255922A1
(en)
|
2020-12-03 |
2023-10-11 |
Century Therapeutics, Inc. |
Genetically engineered cells and uses thereof
|
|
US11661459B2
(en)
|
2020-12-03 |
2023-05-30 |
Century Therapeutics, Inc. |
Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
|
|
US20220193134A1
(en)
|
2020-12-23 |
2022-06-23 |
Crispr Therapeutics Ag |
Co-use of lenalidomide with car-t cells
|
|
JP2024501971A
(en)
|
2020-12-31 |
2024-01-17 |
サナ バイオテクノロジー，インコーポレイテッド |
Methods and compositions for modulating CAR-T activity
|
|
WO2022155265A2
(en)
|
2021-01-12 |
2022-07-21 |
Mitolab Inc. |
Context-dependent, double-stranded dna-specific deaminases and uses thereof
|
|
WO2022189967A1
(en)
|
2021-03-09 |
2022-09-15 |
Crispr Therapeutics Ag |
Genetically engineered t cells with ptpn2 knockout have improved functionality and anti-tumor activity
|
|
KR20230158573A
(en)
|
2021-03-22 |
2023-11-20 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Methods for Assessing Potency of Viral Vector Particles
|
|
AU2022253223A1
(en)
|
2021-04-07 |
2023-09-28 |
Century Therapeutics, Inc. |
Combined artificial cell death/reporter system polypeptide for chimeric antigen receptor cell and uses thereof
|
|
CA3214473A1
(en)
|
2021-04-07 |
2022-10-13 |
Century Therapeutics, Inc. |
Compositions and methods for generating alpha-beta t cells from induced pluripotent stem cells
|
|
KR20230170703A
(en)
|
2021-04-07 |
2023-12-19 |
센츄리 쎄라퓨틱스 인코포레이티드 |
Compositions and methods for generating gamma-delta T cells from induced pluripotent stem cells
|
|
AU2022269643A1
(en)
|
2021-05-05 |
2023-11-02 |
FUJIFILM Cellular Dynamics, Inc. |
Methods and compositions for ipsc-derived microglia
|
|
CA3220168A1
(en)
|
2021-05-26 |
2022-12-01 |
Sarah DICKERSON |
Methods to prevent rapid silencing of genes in pluripotent stem cells
|
|
WO2022251367A1
(en)
|
2021-05-27 |
2022-12-01 |
Sana Biotechnology, Inc. |
Hypoimmunogenic cells comprising engineered hla-e or hla-g
|
|
WO2023287827A2
(en)
|
2021-07-14 |
2023-01-19 |
Sana Biotechnology, Inc. |
Altered expression of y chromosome-linked antigens in hypoimmunogenic cells
|
|
US20240252684A1
(en)
|
2021-07-30 |
2024-08-01 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2)
|
|
US20240254483A1
(en)
|
2021-07-30 |
2024-08-01 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of frataxin (fxn)
|
|
WO2023019226A1
(en)
|
2021-08-11 |
2023-02-16 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy
|
|
EP4384188A1
(en)
|
2021-08-11 |
2024-06-19 |
Sana Biotechnology, Inc. |
Inducible systems for altering gene expression in hypoimmunogenic cells
|
|
JP2024531234A
(en)
|
2021-08-11 |
2024-08-29 |
サナ バイオテクノロジー，インコーポレイテッド |
Genetically modified primary cells for allogeneic cell therapy
|
|
JP2024535677A
(en)
|
2021-08-11 |
2024-10-02 |
サナ バイオテクノロジー，インコーポレイテッド |
Genetically modified cells for allogeneic cell therapy to reduce immediate blood-borne inflammatory responses
|
|
EP4384598A1
(en)
|
2021-08-11 |
2024-06-19 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
|
|
KR20240055838A
(en)
|
2021-09-10 |
2024-04-29 |
후지필름 셀룰러 다이내믹스, 인코포레이티드 |
Compositions of cells derived from induced pluripotent stem cells and methods of using the same
|
|
US20230128917A1
(en)
|
2021-09-14 |
2023-04-27 |
Crispr Therapeutics Ag |
Genetically engineered immune cells having a disrupted cd83 gene
|
|
WO2023070043A1
(en)
|
2021-10-20 |
2023-04-27 |
Yale University |
Compositions and methods for targeted editing and evolution of repetitive genetic elements
|
|
EP4419676A1
(en)
|
2021-10-21 |
2024-08-28 |
Vertex Pharmaceuticals Incorporated |
Hypoimmune cells
|
|
WO2023069790A1
(en)
|
2021-10-22 |
2023-04-27 |
Sana Biotechnology, Inc. |
Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methods
|
|
US20240409934A1
(en)
|
2021-10-25 |
2024-12-12 |
Board Of Regents, The University Of Texas System |
Foxo1-targeted therapy for the treatment of cancer
|
|
JP2024541964A
(en)
|
2021-10-29 |
2024-11-13 |
フジフィルム セルラー ダイナミクス，インコーポレイテッド |
Dopaminergic neurons containing mutations and methods of use thereof
|
|
WO2023081900A1
(en)
|
2021-11-08 |
2023-05-11 |
Juno Therapeutics, Inc. |
Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
|
|
WO2023105244A1
(en)
|
2021-12-10 |
2023-06-15 |
Pig Improvement Company Uk Limited |
Editing tmprss2/4 for disease resistance in livestock
|
|
WO2023111913A1
(en)
|
2021-12-15 |
2023-06-22 |
Crispr Therapeutics Ag |
Engineered anti-liv1 cell with regnase-1 and/or tgfbrii disruption
|
|
CN118647600A
(en)
|
2021-12-16 |
2024-09-13 |
爱康泰生治疗公司 |
Lipids for lipid nanoparticle formulation
|
|
US20230346836A1
(en)
|
2021-12-22 |
2023-11-02 |
Crispr Therapeutics Ag |
Genetically engineered t cells with disrupted casitas b-lineage lymphoma proto-oncogene-b (cblb) and uses thereof
|
|
AU2022421236A1
(en)
|
2021-12-22 |
2024-06-27 |
Sangamo Therapeutics, Inc. |
Novel zinc finger fusion proteins for nucleobase editing
|
|
KR20240137574A
(en)
|
2021-12-23 |
2024-09-20 |
사나 바이오테크놀로지, 인크. |
CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS FOR THERAPY OF AUTOIMMUNE DISEASES AND RELATED METHODS
|
|
AU2022423987A1
(en)
|
2021-12-29 |
2024-07-11 |
Century Therapeutics, Inc. |
Genetically engineered cells having anti-cd19 / anti-cd22 chimeric antigen receptors, and uses thereof
|
|
WO2023131616A1
(en)
|
2022-01-05 |
2023-07-13 |
Vib Vzw |
Means and methods to increase abiotic stress tolerance in plants
|
|
WO2023131637A1
(en)
|
2022-01-06 |
2023-07-13 |
Vib Vzw |
Improved silage grasses
|
|
US20250154503A1
(en)
|
2022-01-14 |
2025-05-15 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for programming t cell phenotypes through targeted gene repression
|
|
CA3247928A1
(en)
|
2022-01-14 |
2023-07-20 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation
|
|
WO2023144199A1
(en)
|
2022-01-26 |
2023-08-03 |
Vib Vzw |
Plants having reduced levels of bitter taste metabolites
|
|
US20250302953A1
(en)
|
2022-02-14 |
2025-10-02 |
Sana Biotechnology, Inc. |
Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
|
|
EP4479416A1
(en)
|
2022-02-17 |
2024-12-25 |
Sana Biotechnology, Inc. |
Engineered cd47 proteins and uses thereof
|
|
TW202340457A
(en)
|
2022-02-28 |
2023-10-16 |
美商凱特製藥公司 |
Allogeneic therapeutic cells
|
|
CA3245130A1
(en)
|
2022-03-01 |
2023-09-07 |
Crispr Therapeutics Ag |
Methods and compositions for treating angiopoietin-like 3 (angptl3) related conditions
|
|
WO2023173123A1
(en)
|
2022-03-11 |
2023-09-14 |
Sana Biotechnology, Inc. |
Genetically modified cells and compositions and uses thereof
|
|
EP4496891A1
(en)
|
2022-03-21 |
2025-01-29 |
CRISPR Therapeutics AG |
Methods and compositions for treating lipoprotein-related diseases
|
|
US20230303713A1
(en)
|
2022-03-23 |
2023-09-28 |
Crispr Therapeutics Ag |
Anti-cd19 car-t cells with multiple gene edits and therapeutic uses thereof
|
|
WO2023180967A1
(en)
|
2022-03-23 |
2023-09-28 |
Crispr Therapeutics Ag |
Anti-cd83 car-t cells with regnase-1 and/or tgfbrii disruption
|
|
US20230302423A1
(en)
|
2022-03-28 |
2023-09-28 |
Massachusetts Institute Of Technology |
Rna scaffolded wireframe origami and methods thereof
|
|
WO2023196982A1
(en)
|
2022-04-08 |
2023-10-12 |
Fate Therapeutics, Inc. |
Chimeric antigen receptor for tumor targeting
|
|
KR20250005097A
(en)
|
2022-04-08 |
2025-01-09 |
페이트 세러퓨틱스, 인코포레이티드 |
Cells having solid tumor targeting scaffolds and uses thereof
|
|
WO2023230613A1
(en)
|
2022-05-27 |
2023-11-30 |
The Broad Institute, Inc. |
Improved mitochondrial base editors and methods for editing mitochondrial dna
|
|
JP2025519448A
(en)
|
2022-06-08 |
2025-06-26 |
センチュリー セラピューティクス，インコーポレイテッド |
Immune effector cells derived from induced pluripotent stem cells genetically engineered with membrane-bound il12 and uses thereof
|
|
EP4536696A1
(en)
|
2022-06-08 |
2025-04-16 |
Century Therapeutics, Inc. |
Genetically engineered cells expressing cd16 variants and nkg2d and uses thereof
|
|
WO2023240212A2
(en)
|
2022-06-08 |
2023-12-14 |
Century Therapeutics, Inc. |
Genetically engineered cells having anti-cd133 / anti-egfr chimeric antigen receptors, and uses thereof
|
|
WO2023242827A2
(en)
|
2022-06-17 |
2023-12-21 |
Crispr Therapeutics Ag |
LIPID NANOPARTICLES (LNPs)-BASED OCULAR DELIVERY
|
|
WO2023248147A1
(en)
|
2022-06-21 |
2023-12-28 |
Crispr Therapeutics Ag |
Methods and compositions for in vivo editing of stem cells
|
|
WO2023248145A1
(en)
|
2022-06-21 |
2023-12-28 |
Crispr Therapeutics Ag |
Compositions and methods for treating human immunodeficiency virus
|
|
AU2023289696A1
(en)
|
2022-06-24 |
2025-01-16 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for reducing low-density lipoprotein through targeted gene repression
|
|
CN119452078A
(en)
|
2022-06-29 |
2025-02-14 |
富士胶片控股美国公司 |
IPSC-derived astrocytes and methods of using the same
|
|
JP2025522812A
(en)
|
2022-06-29 |
2025-07-17 |
クリスパー セラピューティクス アクチェンゲゼルシャフト |
Chimeric antigen receptors targeting GPC-3 and immune cells expressing such chimeric antigen receptors for therapeutic use
|
|
CA3261865A1
(en)
|
2022-07-12 |
2024-01-18 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for targeted transcriptional activation
|
|
WO2024013514A2
(en)
|
2022-07-15 |
2024-01-18 |
Pig Improvement Company Uk Limited |
Gene edited livestock animals having coronavirus resistance
|
|
JP2025523965A
(en)
|
2022-07-22 |
2025-07-25 |
ザ・ジョンズ・ホプキンス・ユニバーシティー |
Dendrimer-enabled targeted intracellular CRISPR/CAS system delivery and gene editing
|
|
WO2024023804A2
(en)
|
2022-07-29 |
2024-02-01 |
Crispr Therapeutics Ag |
Genetically engineered immune cells having disrupted transporter associated with antigen processing binding protein (tapbp) gene
|
|
WO2024023802A2
(en)
|
2022-07-29 |
2024-02-01 |
Crispr Therapeutics Ag |
Genetically engineered immune cells having disrupted transporter associated with antigen processing-2 (tap-2) gene
|
|
WO2024023801A2
(en)
|
2022-07-29 |
2024-02-01 |
Crispr Therapeutics Ag |
Genetically engineered immune cells having disrupted transporter associated with antigen processing-1 (tap-1) gene
|
|
KR20250077608A
(en)
|
2022-08-19 |
2025-05-30 |
튠 쎄라퓨틱스, 인코포레이티드 |
Compositions, systems and methods for controlling hepatitis B virus through targeted gene inhibition
|
|
WO2024064642A2
(en)
|
2022-09-19 |
2024-03-28 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for modulating t cell function
|
|
WO2024062388A2
(en)
|
2022-09-20 |
2024-03-28 |
Crispr Therapeutics Ag |
Genetically engineered immune cells expressing chimeric antigen receptor targeting cd20
|
|
AU2023361162A1
(en)
|
2022-10-11 |
2025-05-29 |
Yale University |
Compositions and methods of using cell-penetrating antibodies
|
|
EP4615960A1
(en)
|
2022-11-09 |
2025-09-17 |
C3S2 GmbH |
Methods for manufacturing engineered immune cells
|
|
WO2024102838A1
(en)
|
2022-11-09 |
2024-05-16 |
Century Therapeutics, Inc. |
Engineered interleukin-7 receptors and uses thereof
|
|
IL320650A
(en)
|
2022-11-10 |
2025-07-01 |
Century Therapeutics Inc |
Genetically engineered cells having anti-nectin4 chimeric antigen receptors, and uses thereof
|
|
WO2024119101A1
(en)
|
2022-12-01 |
2024-06-06 |
Yale University |
Stimuli-responsive traceless engineering platform for intracellular payload delivery
|
|
US20240269189A1
(en)
|
2022-12-19 |
2024-08-15 |
FUJIFILM Holdings America Corporation |
Extracellular vesicle-enriched secretome composition derived from induced pluripotent stem cell derived-microglia and methods of use thereof
|
|
WO2024131917A1
(en)
|
2022-12-23 |
2024-06-27 |
益杰立科(上海)生物科技有限公司 |
Complex and use thereof
|
|
CN120476211A
(en)
|
2022-12-23 |
2025-08-12 |
益杰立科新加坡有限公司 |
Fusions and their uses
|
|
WO2024151541A1
(en)
|
2023-01-09 |
2024-07-18 |
Sana Biotechnology, Inc. |
Type-1 diabetes autoimmune mouse
|
|
WO2024163678A2
(en)
|
2023-02-01 |
2024-08-08 |
Tune Therapeutics, Inc. |
Fusion proteins and systems for targeted activation of frataxin (fxn) and related methods
|
|
WO2024163683A2
(en)
|
2023-02-01 |
2024-08-08 |
Tune Therapeutics, Inc. |
Systems, compositions, and methods for modulating expression of methyl-cpg binding protein 2 (mecp2) and x-inactive specific transcript (xist)
|
|
JP2026504491A
(en)
|
2023-02-03 |
2026-02-05 |
ツェー３エス２ ゲーエムベーハー |
Methods for non-viral production of engineered immune cells
|
|
CN120712355A
(en)
|
2023-02-15 |
2025-09-26 |
阿伯生物技术公司 |
A gene editing method for inhibiting aberrant splicing in the inhibitory microtubule assembly protein 2 (STMN2) transcript
|
|
WO2024192108A1
(en)
|
2023-03-14 |
2024-09-19 |
Evolveimmune Therapeutics, Inc. |
Genetically modified car t cells and methods of making and using the same
|
|
AU2024257643A1
(en)
|
2023-04-21 |
2025-10-16 |
Kite Pharma, Inc. |
Allogenic therapeutic cells with reduced risk of immune rejection
|
|
AU2024264889A1
(en)
|
2023-05-03 |
2025-11-13 |
Sana Biotechnology, Inc. |
Methods of dosing and administration of engineered islet cells
|
|
WO2024238723A1
(en)
|
2023-05-16 |
2024-11-21 |
Omega Therapeutics, Inc. |
Methods and compositions for modulating pcsk9 expression
|
|
WO2024238726A1
(en)
|
2023-05-16 |
2024-11-21 |
Omega Therapeutics, Inc. |
Methods and compositions for modulating methylation of a target gene
|
|
WO2024243236A2
(en)
|
2023-05-22 |
2024-11-28 |
Sana Biotechnology, Inc. |
Methods of delivery of islet cells and related methods
|
|
WO2025004001A1
(en)
|
2023-06-30 |
2025-01-02 |
Takeda Pharmaceutical Company Limited |
Htt repressors and uses thereof
|
|
WO2025019742A1
(en)
|
2023-07-19 |
2025-01-23 |
Omega Therapeutics, Inc. |
Methods and compositions for modulating ctnnb1 expression
|
|
AU2024301706A1
(en)
|
2023-07-21 |
2026-02-05 |
Crispr Therapeutics Ag |
Modulating expression of alas1 (5'-aminolevulinate synthase 1) gene
|
|
WO2025029840A1
(en)
|
2023-07-31 |
2025-02-06 |
Tune Therapeutics, Inc. |
Compositions and methods for multiplexed activation and repression of t cell gene expression
|
|
WO2025029835A1
(en)
|
2023-07-31 |
2025-02-06 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating il-2 gene expression
|
|
WO2025038494A1
(en)
|
2023-08-11 |
2025-02-20 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for lymphoid cell differentiation using targeted gene activation
|
|
WO2025059073A1
(en)
|
2023-09-11 |
2025-03-20 |
Tune Therapeutics, Inc. |
Epigenetic editing methods and systems for differentiating stem cells
|
|
WO2025101938A2
(en)
|
2023-11-10 |
2025-05-15 |
Century Therapeutics, Inc. |
Genetically engineered cells having multi-transmembrane domain chimeric antigen receptors utilizing g protein-coupled receptor scaffolds, and uses thereof
|
|
WO2025106626A1
(en)
|
2023-11-15 |
2025-05-22 |
Century Therapeutics, Inc. |
Genetically engineered cells expressing c-x-c chemokine receptor type 4, and uses thereof
|
|
WO2025186726A1
(en)
|
2024-03-05 |
2025-09-12 |
Crispr Therapeutics Ag |
Modulating expression of agt (angiotensinogen) gene
|
|
WO2025194124A1
(en)
|
2024-03-14 |
2025-09-18 |
Tessera Therapeutics, Inc. |
Modified st1cas9 guide nucleic acids
|
|
WO2025207798A1
(en)
|
2024-03-26 |
2025-10-02 |
Century Therapeutics, Inc. |
Genetically engineered cells having anti-cd123 chimeric antigen receptors, and uses thereof
|
|
WO2025207795A1
(en)
|
2024-03-26 |
2025-10-02 |
Juno Therapeutics, Inc. |
Genetically engineered cells having anti-cd33 / anti-cd123 chimeric antigen receptors, and uses thereof
|
|
WO2025224715A1
(en)
|
2024-04-26 |
2025-10-30 |
King Abdullah Univeristy Of Science And Technology |
Methods for improving precise genome modification and reducing unwanted mutations by crispr-cas editing
|
|
WO2025235563A1
(en)
|
2024-05-07 |
2025-11-13 |
Omega Therapeutics, Inc. |
Epigenetic modulation for upregulation of genes
|
|
WO2025235851A1
(en)
|
2024-05-10 |
2025-11-13 |
Juno Therapeutics, Inc. |
Genetically engineered t cells expressing a cd19 chimeric antigen receptor (car) and uses thereof for allogeneic cell therapy
|
|
WO2025260068A1
(en)
|
2024-06-14 |
2025-12-18 |
Tune Therapeutics, Inc. |
Lipid nanoparticle formulation for delivery of nucleic acids to cells
|
|
WO2026006832A1
(en)
|
2024-06-28 |
2026-01-02 |
University Of Connecticut |
Gene modulation for treating cancer
|
|
WO2026015647A1
(en)
|
2024-07-09 |
2026-01-15 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for cell differentiation using targeted gene activation of dll4 and/or vcam1
|